Increased γ-glutamyltransferase and decreased total bilirubin are associated with metabolic syndrome in Korean postmenopausal women

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 11, 2010, Pages 1623-1628

  Kim, Sang Hwan ^a   Lee, Ji Won ^b   Im, Jee Aee ^c   Hwang, Hee Jin ^a  

^a Catholic Kwandong University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c INTOTO Inc   (South Korea)

Author keywords

Glutamyltransferase; Alanine aminotransferase; Metabolic syndrome; Total bilirubin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; CASE REPORT; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC GROUP; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; KOREAN; LIVER FUNCTION; METABOLIC SYNDROME X; POSTMENOPAUSE; PRIORITY JOURNAL; VIRUS HEPATITIS;

ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; BIOLOGICAL MARKERS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; REPUBLIC OF KOREA; RISK FACTORS;

EID: 78751638886     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.302     Document Type: Article

References (36)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. J Am Med Assoc 2001;285:2486-97.
2. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutritional Examination Survey. J Am Med Assoc 2002;287:356-9.
4. Kim MH, Kim MK, Choi BY, Shin YJ. Prevalence of the metabolic syndrome and its association with cardiovascular diseases in Korea. J Korean Med Sci 2004;9:195-201.
5. Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007;92:895-901.
6. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
7. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-7.
8. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii H, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-8.
9. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity 2006;14:2127-31.
10. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
11. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes 2008;32:772-9.
12. Oda E. The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 2008;31:1285-93.
13. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.
14. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
15. Torgerson JS, Lindroos AK, Sjostrom CD, Olsson R, Lissner L, Sjostrom L. Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obes Res 1997;5:105-14.
16. Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA. Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med 2000;248:230-8.
17. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Kempf J, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004;53:2623-32.
18. Onat A, Hergenç G, Karabulut A, Türkmen S, Doǧan Y, Uyarel H, et al. Serum gamma glutamyltransferase as a marker of metabolic syndrome and coronary disease likelihood in nondiabetic middle-aged and elderly adults. Prev Med 2006;43:136-9.
19. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27:1427-32.
20. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007;27:127-33.
21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
22. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diab Res Clin Pract 2007;75:72-80.
23. Rollason JG. Serum gamma-glutamyl transpeptidase in relation to alcohol consumption. Clin Chem Acta 1972;39:75-80.
24. Kim HC, Choi SH, Shin HW, Cheong JY, Lee KW, Lee HC, et al. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J Gastroenterol 2005;11:5314-21.
25. Hamden K, Carreau S, Ayadi F, Masmoudi H, El Feki A. Inhibitory effect of estrogens, phytoestrogens, and caloric restriction on oxidative stress and hepato-toxicity in aged rats. Biomed Environ Sci 2009;2:381-7.
26. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002;99:16093-8.
27. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001;87:1196-200.
28. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, et al. Serum bilirubin and cardiovascular risk factors in a Chinese population. J Cardiovasc Risk 1996;3:459-63.
29. Madhavan M, Wattingney WA, Srinivasan SR, Berenson GS. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis 1997;131:107-13.
30. Lin LY, Kuo HK, Hwang JJ, Lai LP, Chiang FT, Tseng CD, et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009;203:563-8.
31. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-7.
32. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacks J, Halavaara J, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-58.
33. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-8.
34. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacks J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006;49:755-65.
35. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212.
36. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000;23:1835-9.